- Home
- TELA vs IGC Comparison
TELA vs IGC Comparison
Compare TELA & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TELA | IGC |
|---|---|---|
| Founded | 2012 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.5M | 28.5M |
| IPO Year | 2019 | 2005 |
Fundamental Metrics
Financial Performance| Metric | TELA | IGC |
|---|---|---|
| Price | $0.85 | $0.29 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | $3.31 | ★ $5.00 |
| AVG Volume (30 Days) | 53.3K | ★ 255.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 34.80 | ★ 59.09 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $69,300,000.00 | $1,271,000.00 |
| Revenue This Year | $18.41 | $3.54 |
| Revenue Next Year | $15.20 | $15.12 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 18.56 | N/A |
| 52 Week Low | $0.67 | $0.24 |
| 52 Week High | $2.48 | $0.50 |
Technical Indicators
Market Signals| Indicator | TELA | IGC |
|---|---|---|
| Relative Strength Index (RSI) | 47.43 | 52.43 |
| Support Level | $0.67 | N/A |
| Resistance Level | $1.22 | $0.32 |
| Average True Range (ATR) | 0.09 | 0.02 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 46.27 | 34.91 |
Price Performance
Historical ComparisonAbout TELA TELA Bio Inc.
TELA Bio Inc a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. Its growing product portfolio is purposefully designed to leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. The company's OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.